Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of aflibercept 8 mg versus aflibercept 2 mg for macular edema secondary to retinal vein occlusion
CTR20232610Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in Vein occlusion (RVO), sponsored by Bayer. Started Nov 2023; status: completed.
02
Drugs
aflibercept
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on CTR20232610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232610.